ClinicalTrials.gg
SuspendedNCT00002362Updated Jun 24, 2005

A Comparison of Emtricitabine and Abacavir Used in a Three-Drug Combination in HIV-Infected Patients Who Have Never Taken Anti-HIV Drugs

A Phase 3 interventional study of Abacavir sulfate and Efavirenz in HIV Infections, sponsored by Triangle Pharmaceuticals. Suspended at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2005-06-24.

Sponsored by Triangle Pharmaceuticals · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 57 studies testing abacavir in HIV Infections — 1 open to participants now, 1 under way, 1 of them phase 3. Abacavir · HIV Infections.

Started
1999
with 8 others
Phase 3
16 of 57
1 open now
Registered
1st of 57
by date

Among the 57 studies testing abacavir in HIV Infections, this one is one of 9 that started in 1999, is one of 16 in phase 3, and was the 1st registered.

HIV Infections

4,737 studies on the registry are indexed under HIV Infections; 247 are open to participants now.

Browse HIV Infections studies →

Open to participants now

1 of the 57 studies testing abacavir in HIV Infections is open now. Recruiting first, the newest first:

About abacavir

Abacavir: first FDA approval 1998 (ZIAGEN), first EMA approval 1999. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 159 HIV Infections studies recruiting now, 104 (65%) set no upper age limit and 42 (26%) stop at 75 or younger; 31 take children under 18; 60 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 57 studies testing abacavir in HIV Infections, or all of them as a file.
02

Study summary

This study will look at whether emtricitabine is as safe and effective as abacavir (ABC) when taken with stavudine (d4T) and efavirenz (EFV) in patients who have never taken anti-HIV drugs.

Read the detailed description

Patients are randomized to receive open-label emtricitabine or ABC in combination with stavudine and efavirenz. Viral load and CD4+ cell counts are compared at Weeks 24 and 48. Patients are followed for 48 weeks.

03

Conditions studied

  • HIV Infections

Browse trials for

Keywords

  • Dideoxynucleosides
  • Drug Therapy, Combination
  • Stavudine
  • Reverse Transcriptase Inhibitors
  • abacavir
  • efavirenz
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

You may be eligible if you:

  • Are -positive and generally healthy.
  • Have a viral load of 5,000 copies/ml or more.
  • Have of 200 cells/mm3 or more.
  • Are age 18 or older.
  • Agree to practice sexual abstinence or use effective barrier methods of (such as condoms).

Exclusion criteria

Exclusion Criteria

You will not be eligible if you:

  • Have ever taken anti- drugs for 3 days or more.
  • Have had certain AIDS-related infections.
  • Have had severe diarrhea within the past 30 days.
  • Are unable to eat at least 1 meal a day due to nausea, vomiting, or stomach pain.
  • Are being treated for active tuberculosis (TB).
  • Are pregnant or breast-feeding.
  • Use illegal drugs or alcohol that make it difficult for you to take study drugs or keep clinic appointments.
  • Are taking certain medications, or have certain other conditions or diseases (see the technical summary for more detail).
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
06

Study locations

10 sites
  • Ctr for AIDS Research / Education and Service (CARES)
    Sacramento, California 95814, United States
  • San Francisco Veterans Administration Med Ctr
    San Francisco, California 94121, United States
  • Gary Richmond MD
    Fort Lauderdale, Florida 33316, United States
  • Northstar Med Clinic
    Chicago, Illinois 60657, United States
  • South Jersey Infectious Diseases Inc
    Somers Point, New Jersey 08244, United States
  • North Shore Univ Hosp / Div of Infectious Diseases
    Manhasset, New York 11030, United States
  • Univ of Texas Southwestern Med Ctr of Dallas
    Dallas, Texas 75235, United States
  • Houston Clinical Research Network
    Houston, Texas 77006, United States
  • Univ of Texas / Med School at Houston
    Houston, Texas 77030, United States
  • Univ of Texas Health Sciences Ctr
    San Antonio, Texas 78284, United States
07

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jun 24, 2005, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00002362
Lead sponsor
Triangle Pharmaceuticals
First posted
Aug 31, 2001
Start date
Aug 1999
Last update
Jun 24, 2005
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is suspended, as verified in Mar 2000. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Abacavir · Emtricitabine

Start the discussion